Literature DB >> 27060157

Concomitant origin of the anterior or posterior spinal artery with the feeder of a spinal dural arteriovenous fistula (SDAVF).

Yudhi Adrianto1,2, Ku Hyun Yang1, Hae-Won Koo1, Wonhyoung Park1, Sung Chul Jung1, Jie Eun Park1, Kwang-Kuk Kim3, Sang Ryong Jeon4, Dae Chul Suh1.   

Abstract

BACKGROUND/
OBJECTIVE: The concomitant origin of the anterior spinal artery (ASA) or the posterior spinal artery (PSA) from the feeder of a spinal dural arteriovenous fistula (SDAVF) is rare and the exact incidence is not known. We present our experience with the management of SDAVFs in such cases.
METHODS: In 63 patients with SDAVF between 1993 and 2015, the feeder origin of the SDAVF was evaluated to determine whether it was concomitant with the origin of the ASA or PSA. Embolization was attempted when the patient did not want open surgery and an endovascular approach was regarded as safe and possible. The outcome of the procedure was evaluated as complete, partial, or no obliteration. The clinical outcome was evaluated by Aminoff-Logue (ALS) gait and micturition scale scores.
RESULTS: Nine patients (14%) had a concomitant origin of the ASA or PSA with the feeder. There were two cervical, five thoracic, and two lumbar level SDAVFs. A concomitant origin of the feeder was identified with the ASA (n=7) and PSA (n=2). Embolization was performed in four patients and open surgery was performed in five. Embolization resulted in complete obliteration in three patients and partial obliteration in one. Using the ALS gait and micturition scale, the final outcome improved in six while three cases remained in an unchanged condition over 2-148 months.
CONCLUSIONS: The concomitant origin of the ASA or PSA with the feeder occurs occasionally. Complete obliteration of the fistula can be achieved either by embolization or open surgery. Embolization can be carefully performed in selected patients who are in a poor condition and do not want to undergo open surgery. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Arteriovenous Malformation; Fistula; Intervention; Spine

Mesh:

Year:  2016        PMID: 27060157     DOI: 10.1136/neurintsurg-2016-012267

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  6 in total

1.  Osseous versus Nonosseous Spinal Epidural Arteriovenous Fistulas: Experiences of 13 Patients.

Authors:  Y Song; S H Cho; D W Lee; J J Sheen; J H Shin; D C Suh
Journal:  AJNR Am J Neuroradiol       Date:  2018-12-06       Impact factor: 3.825

2.  Reversible Symptom Aggravation by Intake of Taurine-Rich Foods in Patients with Venous Congestive Myelopathy: Controlled Case Series Study.

Authors:  Dae Chul Suh; Soo Jeong; Yun Hyeok Choi; Su Min Cho; Su Young Yun; A Yeun Son; Young Min Lim; Boseong Kwon; Yunsun Song
Journal:  Neurointervention       Date:  2022-06-15

3.  [Clinical outcomes following microsurgery and endovascular embolization in the management of spinal dural arteriovenous fistula: A meta-analysis study].

Authors:  C W Yuan; Y J Wang; S J Zhang; S L Shen; H Z Duan
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-18

4.  Clinical Characteristics and Treatment Outcomes of Spinal Arteriovenous Malformations.

Authors:  Ji Eun Park; Hae-Won Koo; Hairi Liu; Seung Chul Jung; Danbi Park; Dae Chul Suh
Journal:  Clin Neuroradiol       Date:  2016-09-13       Impact factor: 3.649

5.  New grading system for the clinical evaluation of patients with spinal vascular lesions.

Authors:  Dae Chul Suh; Yunsun Song; Danbi Park; Minkyu Han; Young-Min Lim; Ji Eun Park; Sang Hun Lee; Sang Ryong Jeon; Kwang-Kuk Kim
Journal:  Neuroradiology       Date:  2018-08-14       Impact factor: 2.804

6.  Transdural Segment of the Radicular Vein in Spinal Dural Arteriovenous Fistula.

Authors:  Su Hee Cho; Dae Chul Suh
Journal:  Neurointervention       Date:  2017-03-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.